Sample Name
Sample Code
Sample Name
Sample Code
Sample Name
Sample Code
4
Kingchem
301509
5
Hunan Er-kang Pharmaceutical
300267
CN Stock MarketDetailed Quotes
688073 Bide Pharmatech
- 41.69
- +1.12+2.76%
Market Closed Apr 24 15:00 CST
3.79BMarket Cap31.04P/E (TTM)
42.91High40.31Low19.19KlotVolume42.29Open40.57Pre Close79.49MTurnover4.44%Turnover Ratio32.27P/E (Static)90.88MShares61.6652wk High1.86P/B1.80BFloat Cap28.5052wk Low48.68Limit Up43.23MShs Float112.07Historical High32.46Limit Down6.41%Amplitude28.50Historical Low0.90Dividend TTM41.42Avg Price9.65KlotAsk2.16%Div YieldTTM100Lot Size8.07KlotBid
Bide Pharmatech News
Bide Pharmaceutical's net profit in 2024 increased by 7.17% year-on-year, with the Overseas market becoming the growth engine.
In 2024, Bid achieved an annual revenue of 1.102 billion yuan, a year-on-year increase of 0.93%; the net income attributable to the parent company's shareholders was 0.117 billion yuan, a year-on-year increase of 7.17%; the company stated it will continue to optimize the product structure, deepen its global layout, and increase R&D investment to respond to changes in the industry technology.
With A 27% Price Drop For Bide Pharmatech Co., Ltd. (SHSE:688073) You'll Still Get What You Pay For
Bide Pharmaceuticals: Report for the first quarter of 2025
Bide Pharmatech: 2024 Annual Report
Summary of the 2024 Annual Report.
First Quarter Report of 2025.
Bide Pharmaceutical (688073.SH): In the first quarter, the net income was 30.6931 million yuan, an increase of 17.71% year-on-year.
Gelonghui, April 23丨Pide Pharmaceutical (688073.SH) announced its first-quarter report for 2025, reporting revenue of 0.296 billion yuan, a year-on-year increase of 12.83%; Net income attributable to shareholders of the listed company was 30.6931 million yuan, a year-on-year increase of 17.71%; EPS was 0.34 yuan.
Bid Medicine (688073.SH): plans to use no more than 1 billion yuan of idle funds for Cash / Money Market management.
On April 23, Gelonghui reported that Bid Pharma (688073.SH) announced that the company will use no more than 1 billion yuan of idle own funds for Cash / Money Market management.
The Equity Transfer of the symbol has not been delivered, and Bidu Medicine terminates the significant Assets reorganization.
① Regarding the termination of the merger and acquisition, the company stated that the failure to complete the delivery of 100% equity of the target company as expected has resulted in the inability to achieve the purpose of this Trade. Liu Weidong stated that the termination of this acquisition will not affect the company's established Global Strategy layout; ② Bid Pharma has completed the construction of the R&D center and the upgrade of storage facilities in the USA market last year.
Bidder Pharmaceutical (688073.SH): Termination of the issuance of shares to purchase Assets and raise supporting funds.
On April 14th, Gelonghui reported that Bid Pharmaceutical (688073.SH) announced that the second Board of Directors' nineteenth meeting and the second Supervisory Board's fifteenth meeting would be held on April 14th, 2025, where the "Proposal on Terminating the Issuance of Shares for Asset Acquisition and Raising Matching Funds" was reviewed and approved. The meeting agreed to terminate the issuance of shares for asset acquisition and the raising of matching funds, and authorized the company's management to handle matters related to this termination.
Brokerage morning meeting highlights: The USA has increased tariffs on China, but the impact on these industries in the A-shares may be limited.
In today's brokerage morning meeting, GF SEC believes that the USA's tariffs on China have a limited impact on the A-share Computer Industry; China Securities Co.,Ltd. suggested being Bullish on the Innovative Drugs industry that is currently not affected by tariffs; Galaxy Securities stated that Deep Sea Technology has entered a new stage in Global Strategy, focusing on opportunities in core equipment.
Bid Pharma (688073.SH): has repurchased a total of 0.72% of shares.
Gelonghui, April 1丨Bid Pharma (688073.SH) announced that as of March 31, 2025, the company has cumulatively repurchased 653,303 shares through centralized bidding, accounting for 0.72% of the company's total share capital of 90,882,948 shares. The highest price for the repurchased shares was 53.30 yuan per share, and the lowest price was 47.86 yuan per share, with a total payment of 32,781,887.80 yuan (excluding stamp duty, transaction commissions, and other trading costs).
GTJA: Continuous iteration of anti-tumor therapies, domestic new drugs welcome breakthroughs.
GTJA focuses on products with significant differentiation advantages and leading companies in innovative segments.
Li Tao, the Secretary of the Board of Directors and Chief Financial Officer of Bid Pharma (688073.SH), has resigned.
Bid Medicine (688073.SH) announced that the company's Board of Directors recently received a report from the company's Board of Directors Secretary, Financial Department...
Bid Pharma (688073.SH): No Trade buyback has been conducted.
Glory Financial reported on March 4th that Bid Pharmaceuticals (688073.SH) announced that as of the end of February 2025, the company has not conducted any Trade buybacks.
Bide Pharmaceuticals: 2024 Annual Results Report Announcement
2024 Annual Results Express Announcement
Bid Pharma (688073.SH): The net income for 2024 is 0.12 billion yuan, a year-on-year growth of 12.07%.
On February 25, Glonghui announced that Bid Medical (688073.SH) released its performance report for the fiscal year 2024. During the reporting period, the company achieved revenue of 1,102.0103 million yuan, an increase of 0.93% year-on-year; the net income attributable to the parent company's owners was 122.7925 million yuan, an increase of 13.2207 million yuan, or 12.07%; the net income attributable to the parent company's owners, excluding non-recurring gains and losses, was 108.7928 million yuan, a decrease of 13.7173 million yuan, or a decline of 11.20%. During the reporting period, the changes in the macroeconomic environment, down
Bidwell Pharmaceuticals (688073.SH): Plans to spend 50 million to 0.1 billion yuan to repurchase shares.
On February 7, Gelonghui reported that Bid Pharma (688073.SH) announced that the company's repurchased shares are intended to be used for the company's Stock-based Incentive or employee stock ownership plan at a suitable time in the future. The amount for repurchased shares shall not be less than 50 million yuan (inclusive) and shall not exceed 100 million yuan (inclusive), with the repurchase price not exceeding 72.30 yuan per share (inclusive). Recently, the company obtained a "Loan Commitment Letter" issued by CM BANK Shanghai Branch, agreeing to provide special loan support for the repurchase of the company's shares, with the maximum special loan amount not exceeding 90 million yuan and a term of 36.
Bide Pharmatech to Issue Share to Acquire Assets
Market Insights
Discussing
2025 Buffett shareholders' meeting: What's the new buzz in value investing?
🎙️Discussion 1. In the face of market changes, do you prefer to stick with growth stocks or switch to value stocks? 2. Based on the current
Moomoo News Global
Apr 9 20:29
Learning From Buffett: Investing Wisely Amid Market Volatility Triggered by Trump's Tariffs